Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b Studies

Amir S. Youssef,Mohamed Ismail,Kelong Han,Mindy Magee,Ahmed Nader
DOI: https://doi.org/10.1007/s40121-024-00980-9
2024-05-27
Infectious Diseases and Therapy
Abstract:Bepirovirsen is a novel antisense oligonucleotide in development for chronic hepatitis B virus (HBV) infection therapy. Understanding the impact that clinical characteristics may have on bepirovirsen exposure is important for determining efficacious and well-tolerated dosing regimens. This analysis evaluated demographics and clinical characteristics associated with bepirovirsen exposure using a population pharmacokinetic (PK) analysis.
infectious diseases
What problem does this paper attempt to address?
The paper aims to address the following issues: 1. **Drug Background**: Bepirovirsen is a novel antisense oligonucleotide being developed for the treatment of chronic hepatitis B virus (HBV) infection. Previous studies have shown that bepirovirsen is effective in inducing the loss of hepatitis B surface antigen (HBsAg) and HBV DNA in patients with chronic HBV infection. 2. **Study Objective**: The objective of this study is to characterize factors that may be associated with bepirovirsen exposure through population pharmacokinetic analysis to guide treatment decisions such as dosage, administration timing, and patient selection. 3. **Key Findings**: - A linear three-compartment model was established, which accurately describes the pharmacokinetic characteristics of bepirovirsen. - Chronic HBV infection status, body weight, and Asian versus non-Asian ethnicity were key covariates in the final model. - The results indicate that bepirovirsen exposure increases proportionally at different dose levels and is almost completely cleared within 12 weeks after the last 300 mg dose. - The impact of body weight, Asian ethnicity, or disease status on exposure is not clinically significant, thus there is no need to adjust the bepirovirsen dose based on these characteristics. 4. **Conclusion**: The analysis demonstrates that the linear three-compartment model can accurately describe the pharmacokinetic data of bepirovirsen, and there are no significant differences in exposure among different population characteristics. Therefore, it is not recommended to adjust the bepirovirsen dose based on demographic or baseline characteristics.